GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
GT Biopharma, Inc. (NASDAQ: GTBP) reported its fourth quarter and full-year 2022 results, revealing a net loss of $5.6 million in Q4, down from $18.0 million the previous year. Total cash and equivalents as of December 31, 2022, were $16.5 million, bolstered by a $6.5 million direct offering completed in early January 2023. The company has successfully reduced research and development expenses to $2.8 million in Q4 2022, significantly down from $6.7 million a year earlier. With current cash resources and cost-cutting measures, GT Biopharma anticipates funding operations into Q2 2024, aiming for IND clearance for lead asset GTB-3650 in the first half of 2023.
- Cash position improved with $23.0 million available through offerings and cash on hand.
- Significant reduction in R&D expenses from $6.7 million to $2.8 million in Q4 2022.
- G&A expenses decreased to $2.9 million from $11.9 million year-over-year.
- Net loss of $20.9 million for the year ended December 31, 2022, compared to $58.0 million in 2021.
- Proforma cash of approximately
$23.0 million includes$16.5 million in cash as of December 31, 2022, plus$6.5 million in gross proceeds received from a registered direct offering priced at a premium to market on January 4, 2023. - Cash on hand, coupled with significant recent cost reduction efforts, is expected to provide ample runway to fund operations into Q2 2024; anticipated to be sufficient to achieve IND clearance for GTB-3650 and GTB-5550, and initiate clinical trial activities on GTB-3650.
BRISBANE, CALIFORNIA, March 30, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced fourth quarter and full-year 2022 results for the period ended December 31, 2022.
“We continue to move GT Biopharma’s pipeline development program forward through the advancement of GTB-3650, a second generation nanobody TriKE® for the treatment of CD33+ leukemia which will be followed by GTB-5550 for the treatment of B7H3+ solid tumors. Looking ahead we are on track to submit an investigational new drug (IND) filing with the U.S. Food and Drug Administration for our lead-asset GTB-3650 in the first half of 2023,” said Michael Breen, Executive Chairman and interim Chief Executive Officer. “Moreover, as we move our programs closer to the clinic, we have significantly reduced expenses that will enable us to extend our cash runway into Q2 2024. We also continue to investigate and develop the Company’s TriKE® nanobody platform for multiple additional targets and indications, while actively exploring potential development partnerships for our programs.”
Fourth Quarter Highlights
- Successfully completed a registered direct offering for gross proceeds of
$6.5 million priced at premium to market - Dr. Jeff Miller named Consulting Chief Medical Officer
- Presented novel dual antigen targeting approach for the treatment of acute myeloid leukemia (AML) at the American Society of Hematology's 64th Annual Meeting (ASH 2022)
- Presented two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
Fourth Quarter and Year End 2022 Financial Summary
Cash Position: The Company had cash, cash equivalents and short-term investments of
Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2022 were
General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2022 were
Net Loss: The Company reported a net loss of
About Camelid Antibodies
Camelid antibodies are single domain antibodies (sdAbs) from the Camelidae family of mammals that include llamas, camels, and alpacas. These animals produce two main types of antibodies. One type of antibody camelids produce is the conventional antibody that is made up of two heavy chains and two light chains. They also produce another type of antibody that is made up of only two heavy chains and no light chain. This is known as heavy chain IgG (hcIgG). While these antibodies do not contain the CH1 region, they retain an antigen binding domain called the VHH region. VHH antibodies, also known as single domain antibodies, contain only the VHH region from the camelid antibody. Camelid antibodies have key characteristics, which include high affinity and specificity (equivalent to conventional antibodies), high thermostability, good solubility and strictly monomeric behavior, small size, relatively low production cost, ease of genetic engineering, format flexibility or modularity, low immunogenicity, and a higher penetration rate into tissues.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
GT BIOPHARMA, INC. AND SUBSIDIARIES
Consolidated Balance Sheets
(In Thousands, Except Par Value and Share Data)
| December 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 5,672 | $ | 8,968 | ||||
| Short-term investments | 10,836 | 23,011 | ||||||
| Prepaid expenses and other current assets | 54 | 190 | ||||||
| Total Current Assets | 16,562 | 32,169 | ||||||
| Operating lease right-of-use asset | 165 | - | ||||||
| Deposits | 9 | - | ||||||
| TOTAL ASSETS | $ | 16,736 | $ | 32,169 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 3,140 | $ | 8,189 | ||||
| Accrued expenses | 1,669 | 1,901 | ||||||
| Operating lease liability, current | 110 | - | ||||||
| Line of credit | - | 31 | ||||||
| Derivative liability | 19 | 138 | ||||||
| Total Current Liabilities | 4,938 | 10,259 | ||||||
| Non-current operating lease liability | 64 | - | ||||||
| Total Liabilities | 5,002 | 10,259 | ||||||
| Stockholders’ Equity | ||||||||
| Convertible Preferred stock, par value | 1 | 1 | ||||||
| Common stock, par value | 33 | 32 | ||||||
| Common stock issuable, 0 shares and 327,298 shares at December 31, 2022 and 2021, respectively | - | 1,113 | ||||||
| Additional paid in capital | 686,168 | 674,348 | ||||||
| Accumulated deficit | (674,468 | ) | (653,584 | ) | ||||
| Total Stockholders’ Equity | 11,734 | 21,910 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 16,736 | $ | 32,169 | ||||
GT BIOPHARMA, INC. AND SUBSIDIARIES
Consolidated Statements of Operations
(In Thousands, Except Share Data)
| For the Year Ended | ||||||||
| December 31, | ||||||||
| 2022 | 2021 | |||||||
| Revenues | $ | - | $ | - | ||||
| Operating Expenses: | ||||||||
| Research and development (including | 8,811 | 9,591 | ||||||
| Selling, general and administrative (including | 12,446 | 47,924 | ||||||
| Total Operating Expenses | 21,257 | 57,515 | ||||||
| Loss from Operations | (21,257 | ) | (57,515 | ) | ||||
| Other (Income) Expense | ||||||||
| Interest income | (292 | ) | (38 | ) | ||||
| Interest expense | 8 | 718 | ||||||
| Change in fair value of derivative liability | (119 | ) | (211 | ) | ||||
| Unrealized loss on marketable securities | 30 | 29 | ||||||
| Total Other (Income) Expense | (373 | ) | 498 | |||||
| Net Loss | $ | (20,884 | ) | $ | (58,013 | ) | ||
| Net Loss Per Share - Basic and Diluted | $ | (0.66 | ) | $ | (2.06 | ) | ||
| Weighted average common shares outstanding - basic and diluted | 31,868,024 | 28,155,624 | ||||||
GT BIOPHARMA, INC. AND SUBSIDIARIES
Consolidated Statements of Stockholders’ Equity
(In Thousands)
| Preferred Shares | Common Shares | Common Shares Issuable | Additional Paid-in- | Accumulated | ||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Total | ||||||||||||||||||||||||||||
| Balance, December 31, 2020 | 2,450 | $ | 3 | 5,218 | $ | 5 | - | $ | - | $ | 566,356 | $ | (595,797 | ) | $ | (29,433 | ) | |||||||||||||||||||
| Extinguishment of debt discount upon adoption of ASU 2020-06 | - | - | - | - | - | - | (4,745 | ) | 226 | (4,519 | ) | |||||||||||||||||||||||||
| Conversion of Preferred Series J-1 to common stock | (2,354 | ) | (2 | ) | 692 | 1 | - | - | 1 | - | - | |||||||||||||||||||||||||
| Common shares issued upon mandatory conversion of notes payable and accrued interest | - | - | 11,086 | 11 | 327 | 1,113 | 37,675 | - | 38,799 | |||||||||||||||||||||||||||
| Common shares issued upon exercise of warrants | - | - | 3,074 | 3 | - | - | 16,430 | - | 16,433 | |||||||||||||||||||||||||||
| Issuance of common stock in public offering, net of cost | - | - | 4,945 | 5 | - | - | 24,674 | - | 24,679 | |||||||||||||||||||||||||||
| Issuance of common stock for research and development agreement | - | - | 190 | - | - | - | 1,355 | - | 1,355 | |||||||||||||||||||||||||||
| Issuance of common stock as equity compensation to consultants | - | - | 3,082 | 3 | - | - | 15,337 | - | 15,340 | |||||||||||||||||||||||||||
| Issuance of common stock as equity compensation to officers and board of directors | - | - | 3,775 | 4 | - | - | 16,979 | - | 16,983 | |||||||||||||||||||||||||||
| Fair value of vested stock options | - | - | - | - | - | - | 251 | - | 251 | |||||||||||||||||||||||||||
| Extinguishment of derivative liability | - | - | - | - | - | - | 35 | - | 35 | |||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | (58,013 | ) | (58,013 | ) | |||||||||||||||||||||||||
| Balance, December 31, 2021 | 96 | 1 | 32,062 | 32 | 327 | 1,113 | 674,348 | (653,584 | ) | 21,910 | ||||||||||||||||||||||||||
| Cancellation of common stock previously issued for services | - | - | (291 | ) | - | - | - | - | - | |||||||||||||||||||||||||||
| Cancellation of common stock previously issued to prior CEO | - | - | (1,845 | ) | (2 | ) | - | - | (222 | ) | - | (224 | ) | |||||||||||||||||||||||
| Common stock issued upon conversion of notes payable | - | - | 338 | - | (327 | ) | (1,113 | ) | 1,148 | - | 35 | |||||||||||||||||||||||||
| Issuance of common stock as equity compensation to officers, employees, and board of directors | - | - | 710 | 1 | - | - | 2,521 | - | 2,522 | |||||||||||||||||||||||||||
| Issuance of common stock as equity compensation to consultants | - | - | 527 | 1 | - | - | 2,091 | - | 2,092 | |||||||||||||||||||||||||||
| Fair value of vested stock options | - | - | - | - | - | - | 3,032 | - | 3,032 | |||||||||||||||||||||||||||
| Issuance of common stock in settlement of vendor payable | - | - | 1,222 | 1 | - | - | 3,250 | - | 3,251 | |||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | - | - | (20,884 | ) | (20,884 | ) | |||||||||||||||||||||||||
| Balance, December 31, 2022 | 96 | $ | 1 | 32,723 | $ | 33 | - | $ | - | $ | 686,168 | $ | (674,468 | ) | $ | 11,734 | ||||||||||||||||||||
GT BIOPHARMA, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(In Thousands)
| For the Year Ended | |||||||||||||
| December 31, | |||||||||||||
| 2022 | 2021 | ||||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | |||||||||||||
| Net loss | $ | (20,884 | ) | $ | (58,013 | ) | |||||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||||
| Stock based compensation – consultants and research and development | 2,522 | 16,695 | |||||||||||
| Stock based compensation - officers, employees and board of directors | 2,092 | 16,983 | |||||||||||
| Stock based compensation - vested stock options | 3,032 | 251 | |||||||||||
| Fair value of common stock issued to a noteholder as settlement | 35 | - | |||||||||||
| Convertible notes payable issued for consulting services | - | 720 | |||||||||||
| Change in fair value of derivative liability | (119 | ) | (211 | ) | |||||||||
| Change in operating lease right-of-use assets | 95 | - | |||||||||||
| Gain from extinguishment of line of credit | (31 | ) | - | ||||||||||
| Unrealized loss on marketable securities | 30 | 29 | |||||||||||
| Changes in operating assets and liabilities: | |||||||||||||
| Decrease in prepaid expenses and other current assets | 136 | 174 | |||||||||||
| (Increase) in deposits | (9 | ) | - | ||||||||||
| (Decrease) increase in accounts payable and accrued expenses | (2,030 | ) | 7,077 | ||||||||||
| Decrease in operating lease liability | (86 | ) | - | ||||||||||
| Increase in accrued interest | - | 689 | |||||||||||
| Net Cash Used in Operating Activities | (15,217 | ) | (15,606 | ) | |||||||||
| CASH FLOWS FROM INVESTING ACTIVITIES | |||||||||||||
| Sales (purchases) of investments | 12,145 | (23,040 | ) | ||||||||||
| Net Cash Provided by (Used in) Investing Activities | 12,145 | (23,040 | ) | ||||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES | |||||||||||||
| Proceeds from issuance of common stock | - | 24,679 | |||||||||||
| Cancellation of common stock upon settlement with former officer | (224 | ) | - | ||||||||||
| Proceeds from exercise of warrants | - | 16,433 | |||||||||||
| Proceeds from issuance of notes payable | - | 1,205 | |||||||||||
| Net Cash (Used in) Provided by Financing Activities | (224 | ) | 42,317 | ||||||||||
| Net (Decrease) Increase in Cash | (3,296 | ) | 3,671 | ||||||||||
| Cash at Beginning of Period | 8,968 | 5,297 | |||||||||||
| Cash at End of Period | $ | 5,672 | $ | 8,968 | |||||||||
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | |||||||||||||
| Cash paid during the year for: | |||||||||||||
| Interest | $ | - | $ | - | |||||||||
| Income taxes | $ | - | $ | - | |||||||||
| SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES | |||||||||||||
| Right-of-use assets exchanged for lease liabilities | $ | 260 | $ | - | |||||||||
| Extinguishment of unamortized debt discount and adjustment to accumulated deficit upon adoption of ASU 2020-06 | $ | - | $ | 4,745 | |||||||||
| Common stock issued upon conversion of notes payable and accrued interest | $ | - | $ | 38,799 | |||||||||
| Common stock issued upon settlement of vendor payable | $ | 3,251 | $ | - | |||||||||
| Accounts payable reclassified to convertible notes | $ | - | $ | 525 | |||||||||
| Extinguishment of derivative liabilities | $ | - | $ | 35 | |||||||||
| Conversion of Series J Preferred Stock to Common Stock | $ | - | $ | 2 | |||||||||
FAQ
What were GTBP's financial results for Q4 2022?
How is GTBP's cash position as of December 31, 2022?
What are the anticipated plans for GTBP's lead asset GTB-3650?
What reductions in expenses did GTBP achieve during 2022?
